Keros Therapeutics, Inc. (KROS) Net income 2019–2025
Keros Therapeutics, Inc. (KROS) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
$87.0MFY2025 · since FY2019: -$12.3M → $87.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $87.0M | +146.4% |
| FY2024 | -$187.4M | -22.5% |
| FY2023 | -$153.0M | -46.2% |
| FY2022 | -$104.7M | -78.2% |
| FY2021 | -$58.7M | -29.5% |
| FY2020 | -$45.4M | -267.7% |
| FY2019 | -$12.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS RevenueKROS Net marginKROS Gross profitKROS Gross marginKROS Operating incomeKROS Operating marginKROS Operating cash flowKROS Free cash flowKROS Capital expendituresKROS Return on equityKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →